Isconova and Genocea Biosciences have widened their existing agreement, under which Isconova has given license for using its Matrix M to Genocea Biosciences in vaccines targeting two additional diseases. Currently, Genocea has the right to use Matrix M in vaccines targeting six infectious diseases including programs in its pipeline for herpes simplex virus type-2, Chlamydia trachomatis, and Streptococcus pneumoniae.With this expansion, Genocea has got license to use Matrix M in vaccines for malaria and gonorrhoea.Genocea CEO Chip Clark said a safe and effective adjuvant that elicits strong B and T cell immune response is essential to their aim to prevent or treat infectious diseases. Isconova CEO Lena Soderstrom said they are pleased that a vaccine discovery and development company Genocea has selected Isconova’s Matrix M for use in two additional diseases, thus confirming the strengths of their products.
Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Related stories
- Advertisement -
Latest stories
Related stories
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access theMedia Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
